PROPANC BIOPHARMA, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | $29.0K | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $971.8K | $1.4M | $134.3K | $8.2K | $12.3K | $5.3K | $385.8K | — |
| SG&A Expense | $4.7M | $5.4M | $1.6M | $742.0K | $1.3M | $11.6M | $1.8M | — |
| Operating Income | $-5.7M | $-6.9M | $-1.7M | $-761.2K | $-1.4M | $-11.6M | $-2.2M | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | $3.2M | $4.5M | $1.3M | $93.1K | $5.5K | $3.0K | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $-305.7K | $-72.5K | $-77.5K | $-48.3K | $-60.5K | $-173.9K | $-84.6K | — |
| Net Income | $-7.9M | $-9.4M | $-3.4M | $-829.6K | $-1.4M | $-11.4M | $-2.2M | $-842.5K |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Shares Outstanding (Basic) | 7.95B | 967.36B | 436.87B | 100.99B | 87.56B | 89.43B | 88.10B | — |
| Shares Outstanding (Diluted) | 7.95B | 967.36B | 436.87B | 100.99B | 87.56B | 89.43B | 88.10B | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |